We are live on ! Find out more
FTH

Faeth Therapeutics
FTH

42 hedge funds and large institutions have $37.1M invested in Faeth Therapeutics in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 16 increasing their positions, 9 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 6

78% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 9

64% more capital invested

Capital invested by funds: $22.6M → $37.1M (+$14.4M)

24% more funds holding

Funds holding: 34 → 42 (+8)

0.2% more ownership

Funds ownership: 0.38% → 0.58% (+0.2%)

Holders
42
Holders Change
+8
Holders Change %
+23.53%
% of All Funds
0.74%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
16
Reduced
9
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$5.8M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$3.27M
3
Millennium Management
Millennium Management
New York
+$2.35M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.2M
5
Northern Trust
Northern Trust
Illinois
+$780K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$1.46M
2
FG
Formula Growth
Quebec, Canada
-$976K
3
Morgan Stanley
Morgan Stanley
New York
-$950K
4
MCM
Moore Capital Management
New York
-$711K
5
ZP
Zimmer Partners
New York
-$449K
Name Holding Trade Value Shares
Change 		Change in
Stake
Jane Street
26
Jane Street
New York
$113K +$98.1K +539 New
Bank of America
27
Bank of America
North Carolina
$90K -$28.8K -158 -27%
New York State Common Retirement Fund
28
New York State Common Retirement Fund
New York
$57K +$182 +1 +0.4%
Morgan Stanley
29
Morgan Stanley
New York
$35K -$950K -5,220 -97%
Royal Bank of Canada
30
Royal Bank of Canada
Ontario, Canada
$25K +$15.8K +87 +256%
Citigroup
31
Citigroup
New York
$25K +$18.6K +102 +567%
Legal & General Group
32
Legal & General Group
United Kingdom
$18K +$9.83K +54 +180%
AIP
33
Ameritas Investment Partners
Nebraska
$17K +$8.92K +49 +158%
UBS Group
34
UBS Group
Switzerland
$11K +$2.73K +15 +43%
TRCT
35
Tower Research Capital (TRC)
New York
$8K -$5.83K -32 -45%
IRAG
36
Investment Research & Advisory Group
Georgia
$5K +$12.7K +70 New
BCV
37
Banque Cantonale Vaudoise
Switzerland
$3K – – –
Wells Fargo
38
Wells Fargo
California
$1K -$100K -551 -99%
PA
39
Parallel Advisors
California
$1K +$546 +3 New
US Bancorp
40
US Bancorp
Minnesota
$1K +$910 +5 New
S
41
SignatureFD
Georgia
$1K +$1.27K +7 New
FG
42
Formula Growth
Quebec, Canada
– -$976K -5,000 Closed
ZP
43
Zimmer Partners
New York
– -$449K -2,300 Closed
Alyeska Investment Group
44
Alyeska Investment Group
Illinois
– -$390K -2,000 Closed
Tudor Investment Corp
45
Tudor Investment Corp
Connecticut
– -$274K -1,406 Closed
Two Sigma Advisers
46
Two Sigma Advisers
New York
– -$226K -1,160 Closed
Two Sigma Investments
47
Two Sigma Investments
New York
– -$181K -928 Closed
LC
48
Lindbrook Capital
California
– +$182 +1 New
1
2

FTH Hedge Fund Activity: Q3 2021 in Review

42 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q3 2021, worth a combined $37.1M — up 64% from $22.6M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new FTH positions and 6 closed out — a net gain of 8 holders — while 16 added to existing stakes and 9 trimmed.

The largest buyer was BlackRock, adding an estimated $5.8M. The largest seller was Citadel Advisors, cutting an estimated $1.46M.

  • 42 institutional investors held Faeth Therapeutics (FTH) as of Q3 2021, up from 34 in Q2 2021.
  • Funds reported $37.1M of Faeth Therapeutics stock for Q3 2021, up 64% quarter-over-quarter.
  • 14 funds opened new Faeth Therapeutics positions in Q3 2021 and 6 closed out, a net change of +8 holders.
  • The largest Faeth Therapeutics buyer in Q3 2021 was BlackRock, an estimated $5.8M added.
  • The largest Faeth Therapeutics seller in Q3 2021 was Citadel Advisors, an estimated $1.46M sold.

Based on aggregated 13F filings for Q3 2021.